about
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismFactor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillationOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosisFactor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillationFactor Xa inhibitors for acute coronary syndromesEffective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulantsConsiderations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant eraThe evolution of anticoagulant therapyClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literatureNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismNew parenteral anticoagulants in development.The proof for new oral anticoagulants: clinical trial evidence.Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.Anticoagulation by factor Xa inhibitors.A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Polysulfated trehalose as a novel anticoagulant agent with dual mode of action.Anticoagulation-associated adverse drug events.The effects of dabigatran etexilate on fracture healing in rats: An experimental study.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesMedical management of venous thromboembolism: what the interventional radiologist needs to knowNew insights into the mechanisms of venous thrombosis.Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding.Mechanisms And Management Of Thrombo-Embolism In Atrial FibrillationNeutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.Inhibitors of propagation of coagulation: factors V and X.Unstable angina and non-ST elevation myocardial infarction.Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves.New oral anticoagulants: a view from the laboratory.Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.
P2860
Q24187205-97E64ED5-F332-4124-8C4D-5CA0B66255CFQ24200497-C07DB9B7-C12E-4A61-AFDA-491F913F5B8FQ24200864-F3A9B783-496F-44BD-B329-E0993D30B7E8Q24200867-FF21FBEE-93B8-4143-8960-9252F307B14BQ24234397-B5F73B1C-7030-4C04-A646-8ED81971F1D1Q24234760-982F7C36-D266-4AC8-A284-182E7E8152F4Q26746213-62C0321D-D809-4411-AFC4-9757A75E8352Q26765299-7AF16FA4-9499-48D8-9180-9EF44CF2D476Q26771859-00187C9E-8EDE-41D9-B94E-EBCF21906C44Q26828817-0B8E1C7F-028B-4DF6-9B82-D51E7EB65636Q27497485-26D06E45-5553-4D20-88D8-FAC96A2DF4B9Q28080616-A0DCD87C-89EC-4B51-B0CF-F62F40D3F85EQ28087447-5B52E679-3EEF-4BF3-A3A2-59622E00E62CQ33392647-34613B0C-DFE1-450A-81E2-9BD40558E219Q33397016-32F0A7DA-0EB9-47E2-AAB3-BD9287D82E57Q33936087-F89ADB28-2B38-4D87-9FC7-1F47E9BA6D34Q34128442-62941CA7-F76F-47A2-9BEC-9137C5462E91Q34130097-6690B62A-0437-40D7-A8D6-B4D2B76E9B42Q34402606-6D9A8539-52F8-4B09-AEDB-EEA4D1311956Q34906214-A06E615D-1C97-4971-8F96-92A68FA43CF0Q35239901-BD89BEBA-58F8-4D0F-B602-3F2335C9097AQ35573731-657EB367-807C-450A-AB2E-B66086797F6DQ35645167-43BB048E-E695-45D4-AC80-69E040637674Q35683869-F008CBA1-1C9B-4539-98C8-A204D9185B3CQ35752611-42E4AFD8-BBA7-458F-BF70-F6CF5FE43214Q35948292-76C1ACF8-3EB9-4819-B2EF-AA93A738FE4AQ36068279-45C6A26A-80DC-41A5-AC65-A6E933EA4C34Q36839479-EA7F666E-61FF-4CAF-9622-E3FD457E717BQ37066818-5737CD3F-AC75-4FA7-BA7C-AAF806D205BFQ37114565-DB0EDD54-A1B7-4612-9BB5-7A0FB3BC6759Q37115524-C46D54E2-9D53-4CEC-B1BB-C602855AC5EEQ37261059-5D61DDD2-063D-49D1-A3A9-345933FB1615Q37388007-7EB723C4-8964-473E-B10C-EB2AD19A54D3Q37832237-AAE42DA0-191C-4357-B746-08303110B6AEQ37872338-49DFC10B-E6B4-4BC6-BBD3-D307F5F1F3FDQ37972109-A122FC0B-AE34-49EF-921C-7F1EFDC50EA4Q37982206-1F244278-7496-475F-8313-6C6344AA62C3Q37990454-764216D1-9F04-4A7E-A3D5-CEED03F364BFQ37992582-052B9DE4-0D8F-420D-B47D-0D6E817B0930Q37997628-EC0950D5-E24A-4A73-93A9-A64CF8F05959
P2860
description
im April 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 April 2010
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2010
@uk
name
New Anticoagulants
@en
New Anticoagulants
@nl
type
label
New Anticoagulants
@en
New Anticoagulants
@nl
prefLabel
New Anticoagulants
@en
New Anticoagulants
@nl
P1433
P1476
New anticoagulants
@en
P2093
Jeffrey I Weitz
P304
P356
10.1161/CIRCULATIONAHA.109.853119
P407
P577
2010-04-01T00:00:00Z